Back

Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases

Yao, X.-Y.; Liu, W.; Li, Z.-Y.; Xiong, H.-L.; Su, Y.-Y.; Li, T.; Zhang, S.-Y.; Zhang, X.-J.; Bi, Z.-F.; Deng, C.-X.; Li, C.-Y.; Yuan, Q.; Zhang, J.; Zhang, T.-Y.; Wang, Z.-X.; Ge, S.-x.; Ningshao, X.

2020-07-21 infectious diseases
10.1101/2020.07.18.20156810 medRxiv
Show abstract

Knowledge of the host immune response after natural SARS-CoV-2 infection is essential for informing directions of vaccination and epidemiological control strategies against COVID-19. In this study, thirty-four COVID-19 patients were enrolled with 244 serial blood specimens (38.1% after hospital discharge) collected to explore the chronological evolution of neutralizing (NAb), total (TAb), IgM, IgG and IgA antibody in parallel. IgG titers reached a peak later (approximately 35 days postonset) than those of Nab, Ab, IgM and IgA (20[~]25 days postonset). After peaking, IgM levels declined with an estimated average half-life of 10.36 days, which was more rapid than those of IgA (51.25 days) and IgG (177.39 days). Based on these half-life data, we estimate that the median times for IgM, IgA and IgG to become seronegative are 4.59 (IQR 4.12-5.03), 7.78 (IQR 6.71-9.16) and 42.72 (IQR 33.75-47.96) months post disease onset. The relative contribution of IgM to NAb was higher than that of IgG (standardized {beta} regression coefficient: 0.53 vs 0.48), so the rapid decline in NAb may be attributed to the rapid decay of IgM in acute phase. However, the relative contribution of IgG to NAb increased and that of IgM further decreased after 6 weeks postonset. Its assumed that the decline rate of NAb might slow down to the same level as that of IgG over time. This study suggests that SARS-CoV-2 infection induces robust neutralizing and binding antibody responses in patients and that humoral immunity against SARS-CoV-2 acquired by infection may persist for a relatively long time.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Frontiers in Immunology
638 papers in training set
Top 0.8%
12.8%
2
The Journal of Infectious Diseases
202 papers in training set
Top 0.4%
6.8%
3
PLOS ONE
5266 papers in training set
Top 24%
6.8%
4
Frontiers in Medicine
120 papers in training set
Top 0.3%
6.3%
5
Scientific Reports
3612 papers in training set
Top 23%
4.3%
6
Journal of Medical Virology
140 papers in training set
Top 0.6%
4.1%
7
Cellular & Molecular Immunology
14 papers in training set
Top 0.1%
3.5%
8
Signal Transduction and Targeted Therapy
30 papers in training set
Top 0.1%
3.3%
9
International Journal of Infectious Diseases
129 papers in training set
Top 0.6%
3.2%
50% of probability mass above
10
Pathogens
56 papers in training set
Top 0.3%
2.5%
11
PLOS Pathogens
820 papers in training set
Top 5%
2.4%
12
Microbiology Spectrum
469 papers in training set
Top 5%
2.4%
13
Nature Communications
5641 papers in training set
Top 40%
2.4%
14
eLife
5828 papers in training set
Top 44%
2.1%
15
Virologica Sinica
11 papers in training set
Top 0.1%
1.7%
16
BMC Infectious Diseases
133 papers in training set
Top 2%
1.7%
17
Journal of Infection
78 papers in training set
Top 0.7%
1.5%
18
Open Forum Infectious Diseases
142 papers in training set
Top 2%
1.5%
19
Vaccines
198 papers in training set
Top 2%
1.5%
20
Clinical Infectious Diseases
235 papers in training set
Top 2%
1.1%
21
BMC Medicine
176 papers in training set
Top 4%
1.1%
22
Frontiers in Microbiology
427 papers in training set
Top 7%
1.1%
23
Cell Discovery
57 papers in training set
Top 0.7%
1.1%
24
Cell Reports
1498 papers in training set
Top 25%
1.0%
25
Clinical Immunology
21 papers in training set
Top 0.3%
0.9%
26
Viruses
332 papers in training set
Top 4%
0.8%
27
International Immunopharmacology
15 papers in training set
Top 0.3%
0.8%
28
Clinical & Translational Immunology
22 papers in training set
Top 0.3%
0.8%
29
Journal of Advanced Research
14 papers in training set
Top 0.3%
0.8%
30
Frontiers in Public Health
148 papers in training set
Top 6%
0.8%